PROK
NASDAQProKidney Corp.
Price$1.73-0.02 (-1.14%)
2026-05-212026-08-25
News · 26 weeks37+700%
2026-03-012026-08-23
Mix2090d
- Insider12(60%)
- SEC Filings5(25%)
- Leadership2(10%)
- Other1(5%)
Latest news
25 items- INSIDERDirector Pereira Brian Jg sold $1,067,773 worth of shares (757,164 units at $1.41), closing all direct ownership in the company (SEC Form 4)4 - PROKIDNEY CORP. (0001850270) (Issuer)
- SECSEC Form 144 filed by ProKidney Corp.144 - PROKIDNEY CORP. (0001850270) (Subject)
- SECSEC Form 144 filed by ProKidney Corp.144 - PROKIDNEY CORP. (0001850270) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProKidney Corp.SCHEDULE 13G/A - PROKIDNEY CORP. (0001850270) (Subject)
- SECProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROKIDNEY CORP. (0001850270) (Filer)
- SECSEC Form 10-Q filed by ProKidney Corp.10-Q - PROKIDNEY CORP. (0001850270) (Filer)
- PRProKidney Reports Second Quarter 2026 Financial Results and Business HighlightsCompleted enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027On track for completion of full enrollment for PROACT 1 in the second half of 2026Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experienceEnded Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy compan
- INSIDERDirector Pereira Brian Jg converted options into 757,164 shares (SEC Form 4)4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technical Officer Locke Kenneth Thomas4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERChief Legal Officer Girolamo Todd C converted options into 163,857 shares, increasing direct ownership by 100% to 327,713 units (SEC Form 4)4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 3 filed by new insider Locke Kenneth Thomas3 - PROKIDNEY CORP. (0001850270) (Issuer)
- PRProKidney Appoints Kenneth Locke as Chief Technical OfficerWINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer."Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies," said Bruce Culleton, M.D., CEO of ProKidney. "As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success." Mr.
- INSIDERSEC Form 4 filed by Director Jimenez Santos Jose Ignacio4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Lotvin Alan4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Fox Jennifer A.4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Doyle William F4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Sinha Uma4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Legorreta Pablo G.4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Pereira Brian Jg4 - PROKIDNEY CORP. (0001850270) (Issuer)
- SECProKidney Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PROKIDNEY CORP. (0001850270) (Filer)
- SECProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PROKIDNEY CORP. (0001850270) (Filer)
- SECSEC Form 10-Q filed by ProKidney Corp.10-Q - PROKIDNEY CORP. (0001850270) (Filer)
- PRProKidney Reports First Quarter 2026 Financial Results and Business HighlightsOn track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology (CJASN) in January 2026Ended Q1 2026 with $224.9 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the first q
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ProKidney Corp.SCHEDULE 13D/A - PROKIDNEY CORP. (0001850270) (Subject)
- INSIDERLarge owner Control Empresarial De Capitales S.A. De C.V. converted options into 63,118,645 units of Class A Common Shares (SEC Form 4)4 - PROKIDNEY CORP. (0001850270) (Issuer)
PROK FAQ
6 questionsWhere does PROK stock trade?
ProKidney Corp. (PROK) is listed on NASDAQ.What sector and industry is PROK in?
ProKidney Corp. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ProKidney Corp. go public?
ProKidney Corp. (PROK) completed its IPO in 2021.What are analysts saying about PROK?
ProKidney Corp. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-12-16.What companies are similar to PROK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare PROK side-by-side with any of them on Quantisnow.How can I track PROK on Quantisnow?
Quantisnow aggregates ProKidney Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PROK to receive live email and push alerts on every new disclosure.